Investors weren't impressed with Bristol-Myers Squibb Company's (NYSE: BMY ) Q2 2025 results, with the stock down by 5.8% yesterday. There's a good reason for it. Revenues are taking their sweet time to gain momentum as the company's legacy portfolio drags them backManika is a macroeconomist with over 20 years of experience in industries including investment management, stock broking, investment banking. She also runs the profile Long Term Tips [LTT], which focuses on the generational opportunity in the gre ...